Munir Pirmohamed
Title
Cited by
Cited by
Year
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
M Pirmohamed, S James, S Meakin, C Green, AK Scott, TJ Walley, ...
Bmj 329 (7456), 15-19, 2004
37822004
Estimation of the warfarin dose with clinical and pharmacogenetic data
International Warfarin Pharmacogenetics Consortium
New England Journal of Medicine 360 (8), 753-764, 2009
15632009
Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance
RA Sharma, SA Euden, SL Platton, DN Cooke, A Shafayat, HR Hewitt, ...
Clinical Cancer Research 10 (20), 6847-6854, 2004
12862004
Drug repurposing: progress, challenges and recommendations
S Pushpakom, F Iorio, PA Eyers, KJ Escott, S Hopper, A Wells, A Doig, ...
Nature reviews Drug discovery 18 (1), 41-58, 2019
10232019
HLA-B* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ...
Nature genetics 41 (7), 816-819, 2009
9802009
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer
RA Sharma, HR McLelland, KA Hill, CR Ireson, SA Euden, MM Manson, ...
Clinical Cancer Research 7 (7), 1894-1900, 2001
9492001
HLA-A* 3101 and carbamazepine-induced hypersensitivity reactions in Europeans
M McCormack, A Alfirevic, S Bourgeois, JJ Farrell, D Kasperavičiūtė, ...
New England Journal of Medicine 364 (12), 1134-1143, 2011
9052011
A randomized trial of genotype-guided dosing of warfarin
M Pirmohamed, G Burnside, N Eriksson, AL Jorgensen, CH Toh, ...
N Engl J Med 369, 2294-2303, 2013
7982013
Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes
EC Davies, CF Green, S Taylor, PR Williamson, DR Mottram, ...
PLoS one 4 (2), e4439, 2009
7762009
Adverse drug reactions
M Pirmohamed, AM Breckenridge, NR Kitteringham, BK Park
Bmj 316 (7140), 1295-1298, 1998
748*1998
Active transport of imatinib into and out of cells: implications for drug resistance
J Thomas, L Wang, RE Clark, M Pirmohamed
Blood 104 (12), 3739-3745, 2004
7432004
Emergence and global spread of epidemic healthcare-associated Clostridium difficile
M He, F Miyajima, P Roberts, L Ellison, DJ Pickard, MJ Martin, TR Connor, ...
Nature genetics 45 (1), 109-113, 2013
6652013
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
JA Johnson, L Gong, M Whirl‐Carrillo, BF Gage, SA Scott, CM Stein, ...
Clinical Pharmacology & Therapeutics 90 (4), 625-629, 2011
6512011
Which drugs cause preventable admissions to hospital? A systematic review
RL Howard, AJ Avery, S Slavenburg, S Royal, G Pipe, P Lucassen, ...
British journal of clinical pharmacology 63 (2), 136-147, 2007
6342007
The role of metabolic activation in drug-induced hepatotoxicity
BK Park, NR Kitteringham, JL Maggs, M Pirmohamed, DP Williams
Annu. Rev. Pharmacol. Toxicol. 45, 177-202, 2005
5042005
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
T Eschenhagen, T Force, MS Ewer, GW De Keulenaer, TM Suter, ...
European journal of heart failure 13 (1), 1-10, 2011
4012011
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles
MI Lucena, M Molokhia, Y Shen, TJ Urban, GP Aithal, RJ Andrade, ...
Gastroenterology 141 (1), 338-347, 2011
3912011
Genetic susceptibility to adverse drug reactions
M Pirmohamed, BK Park
Trends in pharmacological sciences 22 (6), 298-305, 2001
3832001
Pharmacogenetics of warfarin: current status and future challenges
M Wadelius, M Pirmohamed
The pharmacogenomics journal 7 (2), 99-111, 2007
3792007
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
NA Limdi, M Wadelius, L Cavallari, N Eriksson, DC Crawford, MTM Lee, ...
Blood, The Journal of the American Society of Hematology 115 (18), 3827-3834, 2010
3562010
The system can't perform the operation now. Try again later.
Articles 1–20